Thrombosis research · 2025
All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chornenki Nicholas L J, Odabashian Roupen, Carrier Marc, Khan Faizan, Lenteejens Jenneke, Stucki Fabian, Wang Tzu-Fei, Tritschler Tobias, Siegal Deborah M
Аннотация
BACKGROUND: Although gastrointestinal (GI) bleeding represents the single most frequent site of anticoagulant-related major bleeding, outcomes after major GI bleeding including mortality are not well characterized and severity may be underappreciated. We aimed to determine 30-day all-cause mortality in adults with major GI bleeding on a direct oral anticoagulant (DOAC).
METHODS: We searched MEDLINE, EMBASE, and Cochrane CENTRAL from inception to May 9, 2024 for randomized controlled trials and cohort studies that reported 30-day all-cause mortality after major GI bleeding in adults treated with a DOAC for venous thromboembolism or atrial fibrillation. Risk of bias was assessed using a modified QUIPS tool for prognostic studies. 30-day all-cause mortality was calculated using the random-effects inverse-variance method.
RESULTS: We included 20 studies comprising 3987 DOAC-treated patients with major GI bleeds. The pooled estimate of 30-day all-cause mortality was 8.4 % (95 % confidence interval [CI], 4.9-12.5; I2 = 83 %). In subgroup analyses, 30-day all-cause mortality was 10.3 % (95 % CI, 6.5-14.7; I2 = 24 %) in prospective studies (9 studies, 675 major GI bleeds), 7.3 % (95 % CI, 2.2-14.4; I2 = 90 %) in retrospective studies (11 studies, 3312 major GI bleeds), 12.9 % (95 % CI, 6.3-21.1; I2 = 44 %) in considered at high risk of bias (9 studies, 387 major GI bleeds), and 6.1 % (95 % CI, 2.9-10.1; I2 = 89 %) in those at low risk of bias (10 studies, 3562 major GI bleeds).
CONCLUSION: DOAC-related major GI bleeding appears to be associated with significant 30-day all-cause mortality. Further research is needed regarding the causes and contributors to mortality in this population to identify patients at high risk and develop mitigation strategies.
METHODS: We searched MEDLINE, EMBASE, and Cochrane CENTRAL from inception to May 9, 2024 for randomized controlled trials and cohort studies that reported 30-day all-cause mortality after major GI bleeding in adults treated with a DOAC for venous thromboembolism or atrial fibrillation. Risk of bias was assessed using a modified QUIPS tool for prognostic studies. 30-day all-cause mortality was calculated using the random-effects inverse-variance method.
RESULTS: We included 20 studies comprising 3987 DOAC-treated patients with major GI bleeds. The pooled estimate of 30-day all-cause mortality was 8.4 % (95 % confidence interval [CI], 4.9-12.5; I2 = 83 %). In subgroup analyses, 30-day all-cause mortality was 10.3 % (95 % CI, 6.5-14.7; I2 = 24 %) in prospective studies (9 studies, 675 major GI bleeds), 7.3 % (95 % CI, 2.2-14.4; I2 = 90 %) in retrospective studies (11 studies, 3312 major GI bleeds), 12.9 % (95 % CI, 6.3-21.1; I2 = 44 %) in considered at high risk of bias (9 studies, 387 major GI bleeds), and 6.1 % (95 % CI, 2.9-10.1; I2 = 89 %) in those at low risk of bias (10 studies, 3562 major GI bleeds).
CONCLUSION: DOAC-related major GI bleeding appears to be associated with significant 30-day all-cause mortality. Further research is needed regarding the causes and contributors to mortality in this population to identify patients at high risk and develop mitigation strategies.